Eledon Pharmaceuticals, Inc. announced updated data on August 6, 2025, from its ongoing open-label Phase 1b trial evaluating tegoprubart for the prevention of organ rejection in kidney transplant patients. Data from patients who remained on tegoprubart for a year showed an overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant.
This eGFR result compares favorably to historical studies using calcineurin inhibitor-based immunosuppression, which typically report aggregate mean eGFRs of approximately 53 mL/min/1.73 m² during the first year. Preliminary abbreviated iBox data also suggested that tegoprubart may improve 5-year graft survival, with scores of -3.75 in the intention-to-treat population and -4.11 in the on-treatment population, compared to a -2.98 historical mean for calcineurin inhibitors.
Tegoprubart continued to be well tolerated, with no cases of death, graft loss, drug-related tremor, or new-onset diabetes reported. All six observed rejection episodes were successfully treated, and patients who remained on tegoprubart after rejection showed full recovery of kidney function, with a mean eGFR of approximately 73 mL/min/1.73 m² at 12 months.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.